Navigation Links
ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
Date:3/6/2009

disease.

The Company believes that microplasmin may represent a major advance in this area, as detaching the vitreous from the retina has been associated with greatly reducing the growth of new blood vessels (neovascularization) on the retina, which plays a fundamental role in the loss of vision in many diabetic patients.

Dr. Steve Pakola, Chief Medical Officer of ThromboGenics, commented, "We are very pleased to announce the completion of enrolment in MIVI II DME. This initial study is an important first step in evaluating microplasmin's effect in the diabetic retinopathy population in general. Microplasmin could represent an important treatment option for this patient population, given numerous studies from various groups showing the clinical benefits of vitreous detachment in diabetic retinopathy."

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product Microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at '/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
2. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
3. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
4. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
5. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
6. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
7. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
8. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
11. Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... the development and commercialization of novel bile acid therapeutics ... of an underwritten public offering of 1,730,000 shares of ... $33.01 per share.  In addition, Intercept has granted the ... additional 259,500 shares of common stock. All ...
(Date:6/18/2013)... , June 18, 2013  Actavis, Inc. (NYSE: ... has filed with the U.S. Securities and Exchange Commission (SEC) ... proposed acquisition of Warner Chilcott plc (NASDAQ: ... Actavis and Warner Chilcott (the "Form S-4"). ... Warner Chilcott have entered into a definitive agreement ...
(Date:6/18/2013)... 18, 2013  Recent regulatory and budget challenges have ... groups at large pharmaceutical companies to effectively educate doctors ... use of their new products. With the pressure to ... crucial that these "Med Ed" groups find ... To address the changes that are transforming the Medical ...
Breaking Medicine Technology:Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2
... Target Enrollment Expected in Fourth Quarter, BERKELEY ... GNTA ) announced that the Data Safety Monitoring ... Genasense (oblimersen sodium),Injection, which is the Company,s lead ... as originally planned after initial review of,blinded safety ...
... unique Ranexa(R) mechanism of action -, CHICAGO, March ... today that ranolazine significantly (p<0.001),shortened the QT interval of ... LQT3, which is caused by a genetic mutation in ... rhythm problems, including,sudden death. Ranolazine also shortened cardiac relaxation ...
Cached Medicine Technology:DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 2DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 3DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 4Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 2Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 3
(Date:6/18/2013)... The Temp1000IS temperature data logger is ... be used to automatically record temperatures between -20 and ... comes with the serial number and device name engraved. ... separately) docking station and can be placed directly into ... of end-caps to download data. The small size of ...
(Date:6/18/2013)... Palo Alto has taken yet another step ... with its recent major long-term solar power commitment. , ... electric power purchase agreements , which together will result in ... photovoltaic electric power per year, which is the equivalent of ... enough power to supply all 65,000+ Palo Alto residents---and then ...
(Date:6/18/2013)... Internationally acclaimed plastic surgeon, Dr. John ... his unique approach to breast augmentation. Dr. Tebbetts’ ... method and highlights the results of Dr. Tebbetts’ ... Tebbetts compares his breast augmentation method to other ... does not necessitate the use drains, bandages, narcotic ...
(Date:6/18/2013)... signaling network between two previously unconnected proteins, exposing a ... growth at its starting point. , A team led ... Cancer Center reported the tie between epidermal growth factor ... a protein vital to the first step in DNA ... . , "MCM7 overexpression marks cell proliferation and is ...
(Date:6/18/2013)... 2013 myCNAjobs announces the addition of ... articles, and tips to the Caregiver Resources Center. , ... the 10,000+ retiring baby boomers each day, the need ... job resources has never been greater. myCNAjobs, ... community, recently launched the first-ever free resource center for ...
Breaking Medicine News(10 mins):Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 3Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2Health News:Scientists catch EGFR passing a crucial message to cancer-promoting protein 2Health News:myCNAjobs Adds New Resources to Growing Caregiver Career Center 2
... an assistant professor at the University of Miami, School ... grant from the Robert Wood Johnson Foundation (RWJF) to ... dating violence among Hispanics. Gonzalez-Guarda is one of just ... the three-year $350,000 Nurse Faculty Scholar award this year. ...
... , WEDNESDAY, Sept. 7 (HealthDay News) -- Breast-feeding ... mothers who bottle-feed or women without children, researchers say. ... mothers and 20 non-mothers also found that aggression in ... This suggests that breast-feeding helps lower the body,s typical ...
... who have received high doses of chemotherapy may find ... research from the Sahlgrenska Academy at the University of ... chemotherapy treatment were two times higher than among those ... the scientific journal Acta Oncologica . Almost one ...
... concerns may prevent children from getting good exercise, according ... examined how families use neighborhood parks. Results ... too closely by hovering "helicopter" parents were less likely ... "It,s a catch-22 for today,s parents, unfortunately. Many ...
... By Ellin Holohan HealthDay Reporter , WEDNESDAY, Sept. ... jeopardize their children,s academic success and harm their family,s finances ... money on cigarettes, according to a new study. The ... with smokers have higher rates of respiratory illness and missed ...
... Reporter , TUESDAY, Sept. 6 (HealthDay News) -- Contrary ... and breast self-exams are useful for the detection of ... screening mammographies and evaluations of palpable masses are important ... co-author of a study to be presented at the ...
Cached Medicine News:Health News:UM Gonzalez-Guarda wins grant from Robert Wood Johnson Foundation 2Health News:UM Gonzalez-Guarda wins grant from Robert Wood Johnson Foundation 3Health News:Chemotherapy can impair speech 2Health News:Helicopter parents can impede child’s ability to play 2Health News:Parents Who Smoke at Home May Risk Kids' Academic Success 2Health News:Parents Who Smoke at Home May Risk Kids' Academic Success 3Health News:Annual Breast Exams, Mammograms Still Key to Detecting Breast Cancer 2Health News:Annual Breast Exams, Mammograms Still Key to Detecting Breast Cancer 3
... Be Set To Any Degree Interval For Marking ... Outer Diameter Opposing Radials Accommodate All Astigmatic Incisions., ... For AKs, LRIs Or Peripheral Corneal Incisions At ... Paired AKs, LRIs Or Peripheral Corneal Incisions 360 ...
... Unique Reversible Speculums Designed To ... By Flipping The Speculums Over, Allowing ... Palpebral Fissures To The Widest Possible ... Operation, Providing Unobstructed Around-The-Clock Access To ...
... The Forceps Are Available In Two Models: ... Are Compressed, The Jaws Close. The Other ... The Handles Are Compressed The Jaws Open., ,The ... To Be Inserted Through A 1.1mm Incision. These ...
... Allows Use Through A 1-Millimeter Incision.,Special ... Approach To The Incision.,Cystotome Tips Are ... Initiate And Complete A Circular Tear.,Titanium ... Improved Ergonomic Feel. Ideal For Bi-Manual ...
Medicine Products: